BD PharmingenTM PE Mouse Anti-Human IP-10

Description

Expression of IP-10 by stimulated human monocytes. Human PBMC were stimulated for 24 hours with Human Interferon-gamma 1500 U/ml final concentration; Cat. No. 554617 in the presence of GolgiStop 2 muM final concentration; Cat. No. 554724 . The PBMC were harvested, fixed, permeabilized, and stained with 0.05 mug of PE-mouse anti-human IP-10 antibody PE-6D4/D6/G2, Cat. No. 555049 following BD Pharmingen staining protocol see Figure, left panel . The data reflect gating on monocytes, based on forward and side scattered light signals. To demonstrate specificity of staining, binding by the PE-6D4/D6/G2 antibody was blocked by preincubation of the fixed/permeabilized cells with excess unlabeled 6D4/D6/G2 antibody 5 mug; middle panel prior to staining with the PE-6D4/D6/G2 antibody. The level of nonspecific staining was assessed using the PE-mouse IgG2a isotype control 0.05 mug; PE-G155-178; Cat. No. 554648; right panel . The quadrant markers for the bivariate dot plots were set based on the autofluorescence control and verified using the unlabeled antibody blocking control. Expression of IP-10 by stimulated human monocytes. Human PBMC were stimulated for 24 hours with Human Interferon-gamma 1500 U/ml final concentration; Cat. No. 554617 in the presence of GolgiStop 2 muM final concentration; Cat. No. 554724 . The PBMC were harvested, fixed, permeabilized, and stained with 0.05 mug of PE-mouse anti-human IP-10 antibody PE-6D4/D6/G2, Cat. No. 555049 following BD Pharmingen staining protocol see Figure, left panel . The data reflect gating on monocytes, based on forward and side scattered light signals. To demonstrate specificity of staining, binding by the PE-6D4/D6/G2 antibody was blocked by preincubation of the fixed/permeabilized cells with excess unlabeled 6D4/D6/G2 antibody 5 mug; middle panel prior to staining with the PE-6D4/D6/G2 antibody. The level of nonspecific staining was assessed using the PE-mouse IgG2a isotype control 0.05 mug; PE-G155-178; Cat. No. 554648; right panel . The quadrant markers for the bivariate dot plots were set based on the autofluorescence control and verified using the unlabeled antibody blocking control. Expression of IP-10 by stimulated human monocytes. Human PBMC were stimulated for 24 hours with Human Interferon-gamma 1500 U/ml final concentration; Cat. No. 554617 in the presence of GolgiStop 2 muM final concentration; Cat. No. 554724 . The PBMC were harvested, fixed, permeabilized, and stained with 0.05 mug of PE-mouse anti-human IP-10 antibody PE-6D4/D6/G2, Cat. No. 555049 following BD Pharmingen staining protocol see Figure, left panel . The data reflect gating on monocytes, based on forward and side scattered light signals. To demonstrate specificity of staining, binding by the PE-6D4/D6/G2 antibody was blocked by preincubation of the fixed/permeabilized cells with excess unlabeled 6D4/D6/G2 antibody 5 mug; middle panel prior to staining with the PE-6D4/D6/G2 antibody. The level of nonspecific staining was assessed using the PE-mouse IgG2a isotype control 0.05 mug; PE-G155-178; Cat. No. 554648; right panel . The quadrant markers for the bivariate dot plots were set based on the autofluorescence control and verified using the unlabeled antibody blocking control. Show More Expression of IP-10 by stimulated human monocytes. Human PBMC were stimulated for 24 hours with Human Interferon-gamma 1500 U/ml final concentration; Cat. No. 554617 in the presence of GolgiStop 2 muM final concentration; Cat. No. 554724 . The PBMC were harvested, fixed, permeabilized, and stained with 0.05 mug of PE-mouse anti-human IP-10 antibody PE-6D4/D6/G2, Cat. No. 555049 following BD Pharmingen staining protocol see Figure, left panel . The data reflect gating on monocytes, based on forward and side scattered light signals. To demonstrate specificity of staining, binding by the PE-6D4/D6/G2 antibody was blocked by preincubation of the fixed/permeabilized cells with excess unlabeled 6D4/D6/G2 antibody 5 mug; middle panel prior to staining with the PE-6D4/D6/G2 antibody. The level of nonspecific staining was assessed using the PE-mouse IgG2a isotype control 0.05 mug; PE-G155-178; Cat. No. 554648; right panel . The quadrant markers for the bivariate dot plots were set based on the autofluorescence control and verified using the unlabeled antibody blocking control. Show More Expression of IP-10 by stimulated human monocytes. Human PBMC were stimulated for 24 hours with Human Interferon-gamma 1500 U/ml final concentration; Cat. No. 554617 in the presence of GolgiStop 2 muM final concentration; Cat. No. 554724 . The PBMC were harvested, fixed, permeabilized, and stained with 0.05 mug of PE-mouse anti-human IP-10 antibody PE-6D4/D6/G2, Cat. No. 555049 following BD Pharmingen staining protocol see Figure, left panel . The data reflect gating on monocytes, based on forward and side scattered light signals. To demonstrate specificity of staining, binding by the PE-6D4/D6/G2 antibody was blocked by preincubation of the fixed/permeabilized cells with excess unlabeled 6D4/D6/G2 antibody 5 mug; middle panel prior to staining with the PE-6D4/D6/G2 antibody. The level of nonspecific staining was assessed using the PE-mouse IgG2a isotype control 0.05 mug; PE-G155-178; Cat. No. 554648; right panel . The quadrant markers for the bivariate dot plots were set based on the autofluorescence control and verified using the unlabeled antibody blocking control. Expression of IP-10 by stimulated human monocytes. Human PBMC were stimulated for 24 hours with Human Interferon-gamma 1500 U/ml final concentration; Cat. No. 554617 in the presence of GolgiStop 2 muM final concentration; Cat. No. 554724 . The PBMC were harvested, fixed, permeabilized, and stained with 0.05 mug of PE-mouse anti-human IP-10 antibody PE-6D4/D6/G2, Cat. No. 555049 following BD Pharmingen staining protocol see Figure, left panel . The data reflect gating on monocytes, based on forward and side scattered light signals. To demonstrate specificity of staining, binding by the PE-6D4/D6/G2 antibody was blocked by preincubation of the fixed/permeabilized cells with excess unlabeled 6D4/D6/G2 antibody 5 mug; middle panel prior to staining with the PE-6D4/D6/G2 antibody. The level of nonspecific staining was assessed using the PE-mouse IgG2a isotype control 0.05 mug; PE-G155-178; Cat. No. 554648; right panel . The quadrant markers for the bivariate dot plots were set based on the autofluorescence control and verified using the unlabeled antibody blocking control.